ChromaDex Corp (NAS:CDXC)
$ 2.84 0.05 (1.79%) Market Cap: 214.53 Mil Enterprise Value: 185.81 Mil PE Ratio: 0 PB Ratio: 7.28 GF Score: 74/100

Q2 2023 Chromadex Corp Earnings Call Transcript

Aug 09, 2023 / 08:30PM GMT
Release Date Price: $1.65 (-0.60%)
Operator

Hello. My name is Ayesha, and I will be your conference operator today. At this time, I would like to welcome everyone to the ChromaDex Second Quarter 2023 Conference Call. (Operator Instructions)

Thank you, Kendall Knysch. You may begin your conference.

Kendall Knysch

Thank you. Good afternoon, and welcome to ChromaDex Corporation's second quarter 2023 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Chief Financial Officer, Brianna Gerber; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao, who will join in the call for Q&A.

Today's conference call may include forward-looking statements, including statements relating to ChromaDex's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Tru Niagen in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest and business prospects and opportunities as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot